• Peritoneal Mesothelioma Treatment Improves Survival Time
  • April 7, 2015
  • Law Firm: Waters Kraus LLP - Dallas Office
  • There seems to be good news for peritoneal mesothelioma patients being treated with cytoreductive surgery and heated chemotherapy (CRS-HIPEC).

    Mesothelioma doctors have published promising findings in multiple new studies involving treatment of peritoneal mesothelioma. Scientists from the University of Montreal authored a study published in the journal Surgical Oncology finding that patients with peritoneal mesothelioma who received a heated rinse of oxaliplatin for half an hour after cytoreductive surgery survived for at least a year. Perhaps more encouraging is that 91 percent survived for three years. Most people diagnosed with mesothelioma survive only about a year from diagnosis.

    Multiple Studies Report Improved Survival Times for Patients Receiving CRS-HIPEC Treatment for Peritoneal Mesothelioma


    In another study of patients at Singapore General Hospital, researchers found that repeated rounds of CRS and HIPEC yielded good results for those with peritoneal mesothelioma. The research results, published in the World Journal of Surgery, confirm that the treatment can prolong survival rates with acceptable post-operative complications.

    CRS/HIPEC is now the standard protocol for treating peritoneal mesothelioma, which strikes about 20 to 30 percent of those diagnosed with mesothelioma each year. Peritoneal mesothelioma occurs in the peritoneum, the lining of the abdominal cavity. As with pleural mesothelioma, peritoneal mesothelioma is linked to asbestos exposure. Doctors are still searching for a cure.